The Quantify team had a great first day at ISPOR and we’re looking forward to what tomorrow has in store. Drop by booth 337 to say hello!
Also – don’t miss our poster on the Economic Burden of Prescription Opioid Abuse in […]
Quantify Research is recognized as one of the 10 most cited publications last year in the renowned journal Alzheimer’s & Dementia!
Our work with Project Alzheimer Value Europe titled “Global estimates on the number of […]
“This cohort patient study provides an invaluable blueprint to inform future treatment decision-making and support optimal use of romosozumab in clinical practice, both in Denmark and across Europe,” said Emmanuel Caeymaex, Executive Vice President, Immunology and U.S. Solutions at […]
Quantify’s Kirk Geale, Emilie Toresson Grip & Puneet Kaushik will be on site and ready to connect.
Keep a lookout for booth #337 to have a chat and learn more about Quantify’s services and expertise, or get in […]
Finland, with its robust healthcare system and comprehensive data infrastructure, provides an ideal environment for conducting real-world evidence (RWE) studies.
In this context, let’s explore the distinctive features of Finnish real-world data (RWD) and how they can contribute towards high-impact research:
1. […]
Since 2020, Quantify Research has been a proud partner to the European Medicines Agency-coordinated ENCePP (European Network for Centres of Pharmacoepidemiology and Pharmacovigilance) initiative.
This network brings together expertise and resources in pharmacoepidemiology and pharmacovigilance across Europe with […]
Turning complex data into valuable insights is crucial. Efficient data visualizations play a key role, revealing compelling stories about historical patterns, current trends, and future opportunities.
In today’s dynamic and data-driven healthcare landscape, there is frequent demand for adaptive analysis tools […]
– Local affiliates may play an important role in the PICO simulation and scoping process : EU teams will rely on Nordic affiliates to provide local market information for PICO simulation and preparation.
Moreover, local affiliates may become an important point […]
About a week ago, FDA approved the very first treatment for patients with liver fibrosis caused by fatty liver disease.
Rezdiffra (resmetirom) is now approved for treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), […]